title: Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
abstract: HLA antibodies and sCD30 levels were detected in the serum sampled from 620 renal graft recipients at 1 year post-transplantation, which were followed up for 5 years. Six-year graft and patient survivals were 81.6% and 91.0%. HLA antibodies were detected in 45 recipients (7.3%), of whom there were 14 cases with class I antibodies, 26 cases with class II, and 5 cases with both class I and II. Much more graft loss was record in recipients with HLA antibodies than those without antibodies (60% vs. 15.1%, p<0.001). Significantly higher sCD30 levels were recorded in recipients suffering graft loss than the others (73.9±48.8 U/mL vs. 37.3±14.6 U/mL, p<0.001). Compared with those with high sCD30 levels, recipients with low sCD30 levels (<50 U/mL) had much better 6-year graft survival (92.4% vs. 46.6%, p<0.001). Further statistical analysis showed that detrimental effect of de novo HLA antibodies and high sCD30 on graft survival was not only independent but also additive. Therefore, post-transplantation monitoring of HLA antibodies and sCD30 levels is necessary and recipients with elevated sCD30 level and/or de novo HLA antibody should be paid more attention in order to achieve better graft survival.
authors.affiliation: Organ Transplant Institute, Fuzhou General Hospital, Fuzhou 350025, China. wangdong1202@medmail.com.cn
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Guojun
authors.initials: G
authors.lastname: Wu
authors.forename: Jinhua
authors.initials: J
authors.lastname: Chen
authors.forename: Ziqiang
authors.initials: Z
authors.lastname: Yu
authors.forename: Weizhen
authors.initials: W
authors.lastname: Wu
authors.forename: Shunliang
authors.initials: S
authors.lastname: Yang
authors.forename: Jianming
authors.initials: J
authors.lastname: Tan
mesh_terms: D000328:Adult; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology / Q000401:mortality; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D017730:Ki-1 Antigen / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D015415:Biomarkers; D006680:HLA Antigens; D017730:Ki-1 Antigen